

# PCHQR Program: 30-Day Unplanned Readmissions for Cancer Patients (PCH-36) Disparity Methods

**November 12, 2024** 

### **Speakers**

#### Gloriana Lopez Montealegre, MA

Research Data and Policy Analyst III
Development, Reevaluation, and Implementation
of Outpatient Outcome/Efficiency Measures

#### Lisa Vinson, BS, BSN, RN

Lead, Prospective Payment System-exempt Cancer Hospital
Quality Reporting (PCHQR) Program
Inpatient and Outpatient Healthcare Quality
Systems Development and Program Support

### **Webinar Chat Questions**

- Please use the Chat tool to submit questions that are pertinent to the webinar topic. Questions submitted through the Chat tool will be addressed in a question-and-answer transcript published at a later date.
- As a reminder, we do not use the raised-hand feature in the Chat tool during webinars.
- Submit additional questions after this event through the <u>QualityNet</u>
   <u>Question and Answer Tool</u>. Include the webinar name, slide number, and speaker name.
- If you have a question unrelated to the current webinar topic, we recommend that you first search for the question in <u>QualityNet</u>
   <u>Question and Answer Tool</u>. If you do not find an answer, then submit your question to us via the same tool.
- We will respond to questions as soon as possible.

### **Acronyms and Abbreviations**

CMS	Centers for Medicare & Medicaid Services
ED	emergency department
FSR	Facility-Specific Report
FY	fiscal year
PCH	Prospective Payment System-exempt Cancer Hospital
PCHQR	Prospective Payment System-exempt Cancer Hospital Quality Reporting
RD	Rate Difference

Back

### **Purpose**

This presentation will provide an overview of the 30-Day Unplanned Readmissions for Cancer Patients (PCH-36) fiscal year (FY) 2025 Facility-Specific Report (FSR) and summarize ways PCHs can use the report to inform approaches to reducing disparities for this measure.

### **Objective**

#### Participants will be able to:

- Identify the PCH-36 measure results in the FY 2025 FSR.
- Understand how the PCHQR Program specifies and calculates PCH-36 disparity results.
- Interpret PCH-36 disparities results in their confidential FSRs.
- Locate resources to learn more about PCH-36 and CMS disparity methods.

Gloriana Lopez Montealegre, MA

#### **PCH-36 FSR Overview**

11/12/2024

### PCHQR Program FSRs (1/2)

- With FSRs, facilities can preview measure results and patient data prior to public reporting.
- The FSR contains measure performance results and patient data in multiple tabs.
- FSRs include the following:
  - Facility-Level Results:
    - Measure performance results include risk-adjusted results for age and comorbid conditions.
    - Detailed patient-level data are used to calculate measure results.
    - Summary of each facility's patient case-mix included.
    - Disparity method results use Within-Facility Disparity Method and Across-Facility Disparity Method. (The latest CMS disparity methods methodology is available on QualityNet on <a href="mailto:cms.gov: PCH Cancer Readmissions Measure Resources">cms.gov: PCH Cancer Readmissions Measure Resources</a>
  - National-Level Results (based on performance at 11 PCHs only):
    - National Performance

## PCHQR Program FSRs (2/2)

- CMS provides FSRs to PCHs participating in the PCHQR Program on select measures:
  - PCH-30/31: Admissions and Emergency Department (ED)
     Visits for Patients Receiving Outpatient Chemotherapy
  - PCH-37: Surgical Treatment Complications for Localized Prostate Cancer
  - PCH-36: 30-Day Unplanned Readmissions for Cancer Patients

### **PCH-36 Measure FSR**

- In July 2024, CMS released FSRs for FY 2025 payment determination under the PCHQR Program for PCH-36: 30-Day Unplanned Readmissions for Cancer Patients.
  - PCH-36 measure performance period for FY 2025 FSRs:
     October 1, 2022–September 30, 2023
- Reportable PCHs: All hospitals in the PCHQR Program that have at least one admission for malignant cancer during the reporting period are included in the measure calculation.
- The FSRs contained, **for the first time**, results for PCH-36 stratified by patients' dual-eligible status\* using CMS disparity methods.
  - Dual-eligible individuals are individuals enrolled in Medicare Part A (Hospital Insurance) and/or Part B (Supplemental Medical Insurance) and are also enrolled in full-benefit Medicaid and/or the Medicare Savings Programs administered by each individual state.
  - Disparity results are **not** publicly reported or used in payment determination.
- \* For ease of reference in this presentation, "duals" and "non-duals" may be used to identify beneficiaries' dual-eligible status.

Gloriana Lopez Montealegre, MA

#### **Disparity Methods**

11/12/2024

### **CMS Disparity Methods**

- CMS developed the disparity methods to examine disparities in health measures using different sociodemographic factors, such as dual-eligible status.
- These methods are applied to the PCH-30/31 chemotherapy measure; PCH-37, Surgical Treatment Complications for Localized Prostate Cancer; and select measures in the Hospital Outpatient Quality Reporting Program.
- There are two disparity methods:
  - The Within-Facility Method seeks to compare results within a facility.
    - Do patients with dual-eligible status at your facility have worse health outcomes than others?
  - The Across-Facility Method seeks to compare facility-level results to a national average.
    - How do outcomes for patients with dual-eligible status at your facility compare to the national average outcome across all those with dual-eligible status?

### Within-Facility Disparity Method

This method measures the difference in the outcome (unplanned readmissions) by calculating an adjusted **Rate Difference (RD)**.


RD=


Risk-Standardized
Readmission Rate for **Duals** 




Risk-Standardized
Readmission Rate for
Non-Duals

Facility A









# Interpreting Within-Facility Disparity Method Rate Difference


- A positive rate difference indicates that patients with dual-eligible status have a higher rate of unplanned readmissions compared to non-dual eligible patients at your facility. This can also be interpreted as patients with dual-eligible status have worse outcomes than non-dual eligible patients at your facility.
- A negative rate difference indicates patients with dualeligible status have a lower rate of unplanned readmissions than non-dual eligible patients at your facility. This can also be interpreted as patients with dualeligible status have better outcomes than non-dual eligible patients at your facility.

### **Across-Facility Disparity Method**

This method compares the risk-adjusted unplanned readmission rate for duals at your facility to the national average for duals across all PCHs.







# Interpreting Across-Facility Disparity Method Outcome Rate

- A rate higher than the national result indicates your facility's patients with dual-eligible status have a higher unplanned readmission rate compared to the national average rate for patients with dual-eligible status.
- A rate lower than the national result indicates your facility's patients with dual-eligible status have a lower unplanned readmission rate compared to the national average rate for patients with dual-eligible status.

Gloriana Lopez Montealegre, MA

#### 2024 FSR PCH-36 Measure Results

11/12/2024

### 2024 FSR Results

CMS Disparity Method Applied:	Provides Information On:
None	Risk-standardized unplanned readmission rate at your facility
Within-Facility Disparity Method	Difference in the risk-adjusted rates of unplanned readmissions between duals and non-duals at your facility
Across-Facility Disparity Method	Risk-adjusted rate of unplanned readmissions for duals at your facility compared to duals at other PCHs in the nation

# Risk-Standardized Unplanned Readmission Rate at Your Facility

Table 1: Your Facility's Performance on Unplanned Readmissions within 30 Days for Cancer Patients Measure

This worksheet contains facility-level and national results.

Your Facility Performance Overview	30-Day Unplanned Readmissions for Cancer Patients Measure	
Comparative Performance at Your Facility [a]	No Different than the National Rate	
Number of Eligible Discharges at Your Facility	1,964	
Risk-Standardized Rate for Your Facility [b]	20.1	
Lower Limit of 95% Interval Estimate	18.5	
Upper Limit of 95% Interval Estimate	21.7	
National Observed Rate [b][c]	20.2	
Additional Performance Information		
Number of Discharges with Outcome for Your Facility	451	
Observed Rate for Your Facility [b]	23.0	
Number of Outcomes in the Nation [c]	4,111	
Number of Eligible Discharges in the Nation [c]	20,371	

# Risk-Standardized Unplanned Readmission Rate at Your Facility

Table 1: Your Facility's Performance on Unplanned Readmissions within 30 Days for Cancer Patients Measure

This worksheet contains facility-level and national results.

Your Facility Performance Overview	30-Day Unplanned Readmissions for Cancer Patients Measure	
Comparative Performance at Your Facility [a]	No Different than the National Rate	
Number of Eligible Discharges at Your Facility	1,964	
Risk-Standardized Rate for Your Facility [b]	20.1	
Lower Limit of 95% Interval Estimate	18.5	
Upper Limit of 95% Interval Estimate	21.7	
National Observed Rate [b][c]	20.2	
Additional Performance Information		
Number of Discharges with Outcome for Your Facility	451	
Observed Rate for Your Facility [b]	23.0	
Number of Outcomes in the Nation [c]	4,111	
Number of Eligible Discharges in the Nation [c]	20,371	

# Risk-Standardized Unplanned Readmission Rate at Your Facility

Table 1: Your Facility's Performance on Unplanned Readmissions within 30 Days for Cancer Patients Measure

This worksheet contains facility-level and national results.

Your Facility Performance Overview	30-Day Unplanned Readmissions for Cancer Patients Measure	
Comparative Performance at Your Facility [a]	No Different than the National Rate	
Number of Eligible Discharges at Your Facility	1,964	
Risk-Standardized Rate for Your Facility [b]	20.1	
Lower Limit of 95% Interval Estimate	18.5	
Upper Limit of 95% Interval Estimate	21.7	
National Observed Rate [b][c]	20.2	
Additional Performance Information		
Number of Discharges with Outcome for Your Facility	451	
Observed Rate for Your Facility [b]	23.0	
Number of Outcomes in the Nation [c]	4,111	
Number of Eligible Discharges in the Nation [c]	20,371	

Gloriana Lopez Montealegre, MA


#### 2024 FSR PCH-36 Measure Disparity Results

11/12/2024

# Performance Categorization for the Within-Facility Disparity Method

For the Within-Facility Disparity Method, facilities are assigned to one of the following three performance categories by comparing their **RD** against a fixed standard, currently defined as a difference of ±1%:

- Better Outcomes for Duals (RD less than -1%)
- Similar Outcomes for Duals and Non-Duals (-1% <= RD <= 1%)</li>
- Worse Outcomes for Duals (RD greater then 1%)



# Performance Categorization for the Across-Facility Disparity Method

For the Across-Hospital Disparity Method, facilities are assigned to one of three performance categories by comparing their unplanned readmission rate for duals against the national result for duals:

- Better than the National Result appears if the facility's result for duals is >1% below the national result.
- **No Different** than the National Result appears if the facility's result for duals is within 1% of the national result (either above or below).
- Worse than the National Result appears if the facility's result for duals is >1% above the national result.

# Reportability of Disparity Methods

CMS Disparity Method	Minimum Patient Volume Required for A Performance Category
Within-Facility Disparity Method	12 duals, or 12 non-duals, or the number of patients is at least 25
Across-Facility Disparity Method	At least 25 duals

# **Understanding your FSR: Within-Facility Table**

Table 5: Summary of Your Facility's Performance on the Within-Facility Disparity Method Applied to the 30-Day Unplanned Readmissions for Cancer Patients Measure

Performance Information	Patients -	Unplanned Readmissions
Comparative Performance at Your Facility [a][b]	For Duals (compared to Non-Duals)	Better outcomes for dual patients
Your Facility's Result [c]	Duals minus Non-Duals	-2.05%
Your Facility's Average Predicted Result [c]	For Duals	23.17%
Your Facility's Average Predicted Result [c]	For Non-Duals	25.22%
Number of Outcomes (Numerator) at Your Facility	For Duals	151
Number of Eligible Cases/Patients (Denominator) at Your Facility	For Duals	644
Number of Outcomes (Numerator) at Your Facility	For Non-Duals	300
Number of Eligible Cases/Patients (Denominator) at Your Facility	For Non-Duals	1,320
Additional National Information		_
Number of Outcomes (Numerator) in the Nation	For Duals and Non-Duals	4,111
Number of Eligible Cases/Patients (Denominator) in the Nation	For Duals and Non-Duals	20,371

# Understanding your FSR: Within-Facility Table

Table 5: Summary of Your Facility's Performance on the Within-Facility Disparity Method Applied to the 30-Day Unplanned Readmissions for Cancer Patients Measure

Performance Information	Patients	Unplanned Readmissions
	▼	▼
Comparative Performance at Your Facility [a][b]	For Duals (compared to Non-Duals)	Better outcomes for dual patients
Your Facility's Result [c]	Duals minus Non-Duals	-2.05%
Your Facility's Average Predicted Result [c]	For Duals	23.17%
Your Facility's Average Predicted Result [c]	For Non-Duals	25.22%
Number of Outcomes (Numerator) at Your Facility	For Duals	151
Number of Eligible Cases/Patients (Denominator) at Your Facility	For Duals	644
Number of Outcomes (Numerator) at Your Facility	For Non-Duals	300
Number of Eligible Cases/Patients (Denominator) at Your Facility	For Non-Duals	1,320
Additional National Information		_
Number of Outcomes (Numerator) in the Nation	For Duals and Non-Duals	4,111
Number of Eligible Cases/Patients (Denominator) in the Nation	For Duals and Non-Duals	20,371

# Understanding your FSR: Within-Facility Table

Table 5: Summary of Your Facility's Performance on the Within-Facility Disparity Method Applied to the 30-Day Unplanned Readmissions for Cancer Patients Measure

Performance Information	Patients -	Unplanned Readmissions
Comparative Performance at Your Facility [a][b]	For Duals (compared to Non-Duals)	Better outcomes for dual patients
Your Facility's Result [c]	Duals minus Non-Duals	-2.05%
Your Facility's Average Predicted Result [c]	For Duals	23.17%
Your Facility's Average Predicted Result [c]	For Non-Duals	25.22%
Number of Outcomes (Numerator) at Your Facility	For Duals	151
Number of Eligible Cases/Patients (Denominator) at Your Facility	For Duals	644
Number of Outcomes (Numerator) at Your Facility	For Non-Duals	300
Number of Eligible Cases/Patients (Denominator) at Your Facility	For Non-Duals	1,320
Additional National Information		_
Number of Outcomes (Numerator) in the Nation	For Duals and Non-Duals	4,111
Number of Eligible Cases/Patients (Denominator) in the Nation	For Duals and Non-Duals	20,371

# Understanding your FSR: Within-Facility Table

Table 5: Summary of Your Facility's Performance on the Within-Facility Disparity Method Applied to the 30-Day Unplanned Readmissions for Cancer Patients Measure

Performance Information	Patients -	Unplanned Readmissions
Comparative Performance at Your Facility [a][b]	For Duals (compared to Non-Duals)	Better outcomes for dual patients
Your Facility's Result [c]	Duals minus Non-Duals	-2.05%
Your Facility's Average Predicted Result [c]	For Duals	23.17%
Your Facility's Average Predicted Result [c]	For Non-Duals	25.22%
Number of Outcomes (Numerator) at Your Facility	For Duals	151
Number of Eligible Cases/Patients (Denominator) at Your Facility	For Duals	644
Number of Outcomes (Numerator) at Your Facility	For Non-Duals	300
Number of Eligible Cases/Patients (Denominator) at Your Facility	For Non-Duals	1,320
Additional National Information		-
Number of Outcomes (Numerator) in the Nation	For Duals and Non-Duals	4,111
Number of Eligible Cases/Patients (Denominator) in the Nation	For Duals and Non-Duals	20,371

# **Understanding your FSR: Across-Facility Table**

Table 6: Summary of Your Facility's Performance on the Across-Facility Disparity Method Applied to the 30-Day Unplanned Readmissions for Cancer Patients Measure

Performance Information	Patients	Unplanned Readmissions
Comparative Performance at Your Facility [a][b]	For Duals	No different than the national rate
Your Facility's Result [c]	For Duals	23.17%
Number of Outcomes (Numerator) at Your Facility	For Duals	151
Number of Eligible Cases/Patients (Denominator) at Your Facility	For Duals	644
Observed Result (Numerator/ Denominator) at Your Facility	For Duals	23.45%
Additional National Information		
Number of Outcomes (Numerator) in the Nation	For Duals	601
Number of Eligible Cases/Patients (Denominator) in the Nation	For Duals	2,553
National Observed Readmission Rate (Numerator/ Denominator)	For Duals	23.54%

# **Understanding your FSR: Across-Facility Table**

Table 6: Summary of Your Facility's Performance on the Across-Facility Disparity Method Applied to the 30-Day Unplanned Readmissions for Cancer Patients Measure

Performance Information	Patients	Unplanned Readmissions
Comparative Performance at Your Facility [a][b]	For Duals	No different than the national rate
Your Facility's Result [c]	For Duals	23.17%
Number of Outcomes (Numerator) at Your Facility	For Duals	151
Number of Eligible Cases/Patients (Denominator) at Your Facility	For Duals	644
Observed Result (Numerator/ Denominator) at Your Facility	For Duals	23.45%
Additional National Information		
Number of Outcomes (Numerator) in the Nation	For Duals	601
Number of Eligible Cases/Patients (Denominator) in the Nation	For Duals	2,553
National Observed Readmission Rate (Numerator/ Denominator)	For Duals	23.54%

# **Understanding your FSR: Across-Facility Table**

Table 6: Summary of Your Facility's Performance on the Across-Facility Disparity Method Applied to the 30-Day Unplanned Readmissions for Cancer Patients Measure

Performance Information	Patients -	Unplanned Readmissions
Comparative Performance at Your Facility [a][b]	For Duals	No different than the national rate
Your Facility's Result [c]	For Duals	23.17%
Number of Outcomes (Numerator) at Your Facility	For Duals	151
Number of Eligible Cases/Patients (Denominator) at Your Facility	For Duals	644
Observed Result (Numerator/ Denominator) at Your Facility	For Duals	23.45%
Additional National Information		
Number of Outcomes (Numerator) in the Nation	For Duals	601
Number of Eligible Cases/Patients (Denominator) in the Nation	For Duals	2,553
National Observed Readmission Rate (Numerator/ Denominator)	For Duals	23.54%

Lisa Vinson, BS, BSN, RN

#### **PCH-36 Resources**

11/12/2024

### **QualityNet Resources**

#### **QualityNet Measures Page**



#### **PCH-36 Overview**

Overview

Methodology

Reports

Resources

#### Cancer Readmissions Measure (PCH-36)

The 30-Day Unplanned Readmissions for Cancer Patients measure (PCH-36) provides facilities with information to improve the quality of care delivered for adult patients with cancer. This measure calculates the rate of unplanned readmissions within 30 days of discharge from an eligible index admission for Medicare fee-for-service patients diagnosed with cancer.

For more information on the measure, refer to the <u>frequently asked questions</u> document on the <u>Resources</u> page.

#### Fiscal Year (FY) 2025

The Centers for Medicare & Medicaid Services (CMS) began reporting results for PCH-36, confidentially, through the Prospective Payment System (PPS)-Exempt Cancer Hospital Quality Reporting (PCHQR) Program. These data were delivered through facility-specific reports (FSRs) in the summer of 2024; they were calculated using data collected from October 1, 2022, through September 30, 2023, and will be publicly reported beginning in the fall of 2024.


For more information on PCH-36 FSRs, please refer to the Reports page.

#### More Information


Please submit questions about the Cancer Readmissions measure to the QualityNet Question and Answer tool. When submitting a question through the Q&A tool, please select PCH—Cancer Hosp. Quality Reporting as the Program and PCH-36: 30-Day Unplanned Readmissions for Cancer Patients as the Topic. To ensure proper handling of inquiries, please reference your facility's CMS Certification Number (CCN).

Please do NOT email a copy of your FSR or submit patientidentifiable information (such as


### **PCH-36 Methodology**



### **PCH-36 Reports**



### **PCH-36 Resources**




Lisa Vinson, BS, BSN, RN

# **QualityNet PCHQR Program Notifications and Question and Answer Tool**


11/12/2024

# Subscribe to Program Notifications


#### **QualityNet Home Page**




### **User Information**



### Program Selection and Sign Up




# Accessing the QualityNet Question and Answer Tool




### **Ask a Question**

#### **QualityNet Question and Answer Tool**



### **Submit a Question**



PCHQR Program: 30-Day Unplanned Readmissions for Cancer Patients (PCH-36) Disparity Methods

#### **Closing Remarks**

11/12/2024

### **Disclaimer**

This presentation was current at the time of publication and/or upload onto the Quality Reporting Center and QualityNet websites. Any links to Medicare online source documents are for reference use only. In the case that Medicare policy, requirements, or guidance related to this presentation change following the date of posting, this presentation will not necessarily reflect those changes; given that it will remain as an archived copy, it will not be updated.

This presentation was prepared as a service to the public and is not intended to grant rights or impose obligations. Any references or links to statutes, regulations, and/or other policy materials included in the presentation are provided as summary information. No material contained therein is intended to take the place of either written laws or regulations. In the event of any conflict between the information provided by the presentation and any information included in any Medicare rules and/or regulations, the rules and regulations shall govern. The specific statutes, regulations, and other interpretive materials should be reviewed independently for a full and accurate statement of their contents.